Skip to main content

2022 CTOS Annual Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Allison Lim, PharmD

SpringWorks Therapeutics
Stamford, Connecticut, United States

Presentation(s):

Paper 80 - DEFI: A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL OF NIROGACESTAT VERSUS PLACEBO FOR PROGRESSING DESMOID TUMORS/AGGRESSIVE FIBROMATOSIS
Saturday, November 19, 2022
1:30 PM – 1:42 PM
Paper 81 - PSYCHOMETRIC PROPERTIES AND MEANINGFUL CHANGE THRESHOLDS (MCT) OF THE GOUNDER/DESMOID TUMOR RESEARCH FOUNDATION DESMOID SYMPTOM/IMPACT SCALE (GODDESS) AS ASSESSED IN THE PHASE 3 DEFI TRIAL
Saturday, November 19, 2022
1:30 PM – 1:42 PM